| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Kayyem Jon Faiz is a Director at INBX, with reported holdings spanning 2 companies. Recent filings cover 15 purchases and 0 sales. Those positions are worth an estimated $43.7M at current prices.
Our model assigns Kayyem Jon Faiz a middling insider score of 51/100, based on 7 past trades. Over a 12-month horizon, 42.9% of those trades were profitable, with an average 12-month return of +15.9%.
Kayyem Jon Faiz's largest disclosed position is in INBX as Director, worth about $43.4M. Net of sales, the recent Form 4 record there shows accumulation of 466,521 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | INBX Inhibrx Biosciences, Inc. | Director | Buy | 5,000 | $100.00 | $500,000.00 | +1.2% | - | - | |
| Sep 16, 2026 | INBX Inhibrx Biosciences, Inc. | Director | Buy | 5,000 | $100.00 | $500,000.00 | +1.2% | - | - | |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc. | Director | Buy | 5,000 | $113.52 | $567,580.00 | +1.2% | - | - | |
| Nov 20, 2024 | INBX Inhibrx Biosciences, Inc. | Director | Buy | 107,186 | $14.21 | $1,523,619.50 | -287.0% | -6.9% | +468.7% | |
| Jun 5, 2024 | INBX Inhibrx Biosciences, Inc. | Director | Buy | 57,549 | $17.32 | $997,024.17 | +5.3% | -5.6% | -23.7% | |
| Jun 4, 2024 | INBX Inhibrx Biosciences, Inc. | Director | Buy | 286,786 | $17.18 | $4,927,579.86 | +35.6% | -7.3% | -24.5% | |
| Nov 21, 2022 | BDSX Biodesix Inc | Director | Buy | 173,913 | $1.15 | $199,999.95 | New | +76.9% | +1.5% |